Felzartamab

菲泽妥单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameFelzartamab
Drug Alias NameMOR-03087TJ-202MOR-202MOR 202HBIB-202 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsPhagocytes stimulantsAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationLupus Erythematosus, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesMorphosys Ag
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdDSM Biologics IncHuman Immunology Biosciences Inc +[10] 
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationRejection of renal transplantationVasculitis +[9] 
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A